A KRAS drug is likely coming — fast — as the FDA points Amgen’s frontrunner to a looming finish line
Amgen got the oncology world excited with a first look at the potential for a KRAS drug to end a decades-long roadblock in R …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
